Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Total Current Liabilities (2020 - 2025)

Universe Pharmaceuticals' Total Current Liabilities history spans 6 years, with the latest figure at $13.2 billion for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 35.15% to $13.2 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $13.2 billion, a 35.15% decrease, with the full-year FY2025 number at $13.2 billion, down 35.15% from a year prior.
  • Total Current Liabilities hit $13.2 billion in Q3 2025 for Universe Pharmaceuticals, down from $20.3 billion in the prior quarter.
  • Over the last five years, Total Current Liabilities for UPC hit a ceiling of $20.3 billion in Q3 2024 and a floor of $10.2 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $4.2 billion across 5 years, with a median of $17.2 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: crashed 100.0% in 2021 and later surged 147584.19% in 2024.
  • Tracing UPC's Total Current Liabilities over 5 years: stood at $11.2 million in 2021, then grew by 16.83% to $13.1 million in 2022, then increased by 5.01% to $13.8 million in 2023, then surged by 147584.19% to $20.3 billion in 2024, then crashed by 35.15% to $13.2 billion in 2025.
  • Business Quant data shows Total Current Liabilities for UPC at $13.2 billion in Q3 2025, $20.3 billion in Q3 2024, and $20.6 million in Q1 2024.